MedTrace Logo

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00135330 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 137

Last updated 2015-04-07

Study results available
· View outcomes & findings →

Summary

This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

exenatide

subcutaneous injection, 5mcg or 10mcg, twice a day

DRUG

rosiglitazone

oral tablet, 2mg or 4mg, twice a day

Sponsors & Collaborators

Principal Investigators

  • James Malone, MD · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00135330 on ClinicalTrials.gov